Ryan MacDonald, an analyst from Needham, reiterated the Buy rating on Omada Health, Inc.. The associated price target was raised to $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan MacDonald has given his Buy rating due to a combination of factors that highlight Omada Health, Inc.’s strong market position and growth potential. The company reported impressive third-quarter results for fiscal year 2025, with revenue and adjusted EBITDA surpassing expectations. This performance was driven by a significant increase in member additions, showcasing the effectiveness of Omada’s engagement strategies.
Furthermore, the company is not just thriving in the current year; it is also well-positioned for future success. The momentum from a robust selling season has resulted in double-digit growth in client acquisitions, and new channel partnerships are already yielding positive outcomes with multi-condition customer wins. These developments suggest that Omada is on track for continued profitable growth into fiscal year 2026, with expectations of nearly 50% growth. MacDonald anticipates that Omada will capture more market share as the adoption of cardiometabolic health solutions accelerates, driven by the GLP-1 trend.
According to TipRanks, MacDonald is a 3-star analyst with an average return of 2.0% and a 42.57% success rate. MacDonald covers the Technology sector, focusing on stocks such as Duolingo, Liveperson, and Asure.
In another report released today, Barclays also maintained a Buy rating on the stock with a $29.00 price target.